NCT06873828Not yet recruitingPhase 3
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring : A Prospective Superiority Study
Source: ClinicalTrials.gov · Last updated 13 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
* Validation of validity, superiority, and safety of data analysis results using AT-Patch compared to 48-hour Holter test results * Number of subjects: 100 (including 10% dropout rate) * Performance and safety were verified by simultaneously attaching a 48-hour Holter and a wearable Holter device (ATP-C75 or ATP-C135).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 26 Feb 2025
- Start date
- Mar 2025
- Primary completion date
- Oct 2025
- Lead sponsor
- Yonsei University
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06873828
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 100
- From Mar 2025 to the primary completion date, Oct 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Those with sensitive or allergic skin, skin diseases such as skin cancer or rashes
Other
- Those judged by the investigator to be unsuitable for this clinical trial or those who may increase the risk due to participation in the clinical trial
- Those with pacemakers, implantable cardioverter-defibrillators, or other implantable electrical devices
- Pregnant women
Who the study is looking for
- Male and female subjects aged 19 years or older
- Subjects diagnosed with hypertrophic cardiomyopathy who require 48-hour Holter examination
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.